Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management
This real-world analysis provides insight into the timing of neutrophil count recovery with dosing schedule modification of venetoclax and G-CSF use in patients with newly-diagnosed AML receiving VEN/AZA, informing timing of the use of antifungal prophylaxis for patients at higher risk.
Authors
- Nobuhiko Uoshima (ORCID: https://orcid.org/0009-0005-1635-2785)
- Shuichi Ota
- Tatsunori Goto (ORCID: https://orcid.org/0000-0002-0314-9498)
- Ryota Imanaka
- Hiroki Numata
- Jun Ando (ORCID: https://orcid.org/0009-0002-3972-9969)
- Goichi Yoshimoto
- Akihito Matsuoka (ORCID: https://orcid.org/0000-0001-7726-9137)
- Tetsuo Morita
- Atsuko Tsutsui
- Yuna Katsuoka
- Hideyuki Hashiba
- Satoru Hara
Institutions
- Juntendo University (JP)
- Sakai Municipal Hospital (JP)
- Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP)
- Saga-Ken Medical Centre Koseikan (JP)
- Sapporo Hokuyu Hospital (JP)
- Sendai Medical Center (JP)
- ABB (Japan) (JP)
- Japanese Red Cross Nagoya Daiichi Hospital (JP)
- Ebina General Hospital (JP)
- Japanese Red Cross Society Kyoto Daini Hospital (JP)
- Chiba Rosai Hospital (JP)
- AbbVie (Japan)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1007/s40487-025-00329-3
- Citations
- 2
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.54